source
- BioMarin drops BMN 401 after Phase 3 trial misses clinical endpoints, ending $270M Inozyme assetBioMarin announced it will stop development of BMN 401, an enzyme replacement therapy acquired in its $270 million purchase of Inozyme Pharma. The decision follows the Phase 3 ENERGY trial in pati…
- FDA issues complete response letter rejecting ITM’s neuroendocrine tumor drug over manufacturing concernsThe U.S. Food and Drug Administration sent a complete response letter to ITM Isotopes Technologies, refusing approval of its lead candidate for gastroenteropancreatic neuroendocrine tumors because…